News
RPTX
3.300
-1.79%
-0.060
Weekly Report: what happened at RPTX last week (0415-0419)?
Weekly Report · 3d ago
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Repare Therapeutics (RPTX) with a price target of $15.00. The company’s stock price has dropped 30.31% in the past six months. Repare is a precision oncology company developing drugs for ovarian cancer.
TipRanks · 3d ago
Private equity firms invested in Repare Therapeutics Inc. (NASDAQ:RPTX) copped the brunt of last week's US$24m market cap decline
Private equity firms own 34% of Repare Therapeutics Inc. (NASDAQ:RPTX) with 54% of the company. The company has a total of 5 major shareholders with a majority of the stock. The top 5 shareholders of the firm are private equity firms with a 34% stake. The majority of shares are owned by five private equity companies. RepareTherapeutics has a market capitalization of just US$154m. It's important to look at the diversity of shareholders in a company to understand its true nature.
Simply Wall St · 04/16 11:35
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche announced topline data from Phase 3 STARGLO study of Columvi in certain subset of patients with diffuse large B-cell lymphoma. Earlier this year, Roche terminated two cancer drug deals. The drug is the first fixed-duration antibody to receive FDA accelerated approval.
Benzinga · 04/15 12:56
Weekly Report: what happened at RPTX last week (0408-0412)?
Weekly Report · 04/15 09:18
Weekly Report: what happened at RPTX last week (0401-0405)?
Weekly Report · 04/08 09:19
Repare Therapeutics Inc.: Statement of changes in beneficial ownership of securities
Press release · 04/02 06:25
Weekly Report: what happened at RPTX last week (0325-0329)?
Weekly Report · 04/01 09:19
Weekly Report: what happened at RPTX last week (0318-0322)?
Weekly Report · 03/25 09:19
Weekly Report: what happened at RPTX last week (0311-0315)?
Weekly Report · 03/18 09:19
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. Investors who purchased Repare securities are encouraged to assist the investigation. Repare’s stock price fell 15.58% on February 12, 2024.
Barchart · 03/15 13:35
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Repare Therapeutics Inc. Shares have lost 30% in the last month. The company's price-to-sales ratio of 4.4x is lower than the wider Biotechs industry. RepareTherapeutics could be doing better as its revenue growth has been going backwards. However, the company's forecast for sliding revenue doesn't match the industry's growth.
Simply Wall St · 03/12 10:07
Weekly Report: what happened at RPTX last week (0304-0308)?
Weekly Report · 03/11 09:18
Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead
TipRanks · 03/08 11:35
Weekly Report: what happened at RPTX last week (0226-0301)?
Weekly Report · 03/04 09:19
Repare Therapeutics Full Year 2023 Earnings: Misses Expectations
Repare Therapeutics missed revenue and earnings estimates by 14% and 11%. The company's shares are up 11% from a week ago. Revenue is forecast to grow 27% in the next 3 years. The company is showing 3 warning signs in our investment analysis.
Simply Wall St · 03/01 10:18
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. Is a leading clinical-stage precision oncology company. Members of its senior management team will participate at two upcoming investor conferences. The Company uses its genome-wide, CRISPR-enabled SNIPRx platform to discover and develop cancer therapies.
Barchart · 02/29 06:05
SHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) Investors
TipRanks · 02/28 21:20
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
TipRanks · 02/28 19:50
Repare Therapeutics Reports Promising 2023 Progress
TipRanks · 02/28 16:37
More
Webull provides a variety of real-time RPTX stock news. You can receive the latest news about Repare Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.